基因技術 GENE 深 滬
交易中 11-07 10:42:39 美东时间
0.765
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.765
- 總市值 370.81万
- 52周最高 3.59
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6666
- 委 比 0.00%
- 總股本 484.72万
- 歷史最高 810.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.6666
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Syngene Enhances Biologics Facility with ADC Bioconjugation
Syngene International Ltd. ( ($IN:SYNGENE) ) has shared an announcement. Syngen...
10-24 01:13
HURRICANE ANNOUNCES MODEL REFRESH FOR SUNDECK 2690
ELKHART, Ind., Oct. 23, 2025 /PRNewswire/ -- Hurricane Boats, legendary innovator in versatile deck boat designs, announced today it has redesigned the classic, Yacht Series Hurricane SunDec...
10-24 00:17
Evernorth to Go Public With Over $1 Billion in Gross Proceeds
Transaction will create the largest public XRP treasury company SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- Evernorth Holdings Inc., a newly formed Nevada corporation ("Evernorth") that wil...
10-20 20:00
Syngene Launches ‘Saksham Niveshak’ Campaign to Secure Shareholder Dividends
Syngene International Ltd. ( ($IN:SYNGENE) ) has provided an update. Syngene In...
10-19 00:23
2025生物制造产业大会在广州国际生物岛举行 广东生物制造剑指万亿元规模
10月11日，2025生物制造产业大会在广州国际生物岛举行。此次大会以“广聚合成，智造先机”为主题，围绕生物制造产业政策、生物制造创新促进中心建设等内容，汇聚政...
10-12 08:07
调研汇总：易方达、富国、睿远基金等86家明星机构调研西藏药业！
登录新浪财经APP 搜索【信披】查看更多考评等级 西藏药业 重点机构：易方达基金、富国基金、睿远基金 调研摘要： 1、公司收购锐正基...
10-09 19:05
快讯：2025肠胃益生菌这品牌效果好！五大品牌推荐，选它不踩雷
现代生活中，饮食失衡、压力过载、抗生素滥用等因素持续冲击肠胃健康，腹胀、反酸、幽门螺杆菌感染、肠易激综合征（IBS）等问题频发。益生菌作为调节肠道微生态的关键手...
10-09 18:02
Precision BioSciences Opens First U.S. ELIMINATE-B Site At Massachusetts General Hospital, Actively Recruiting Chronic Hepatitis B Patients
Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple global clinical trial sites -Phase 1 ELIMINATE-B trial for PBGENE-HBV is progressing and on
10-07 19:16
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Longeveron Inc. is set to participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, in New York, where it will hold one-on-one meetings with investors. The company, which focuses on developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, is advancing Laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy with broad therapeutic potential. Longeveron...
10-06 13:15
Precision BioSciences Announces Late-Breaking Poster Presentation At WMS 2025; To Highlight Latest Long-Term Preclinical Efficacy And Durability Data Supporting PBGENE-DMD For Duchenne Muscular Dystrophy Treatment
- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy-- On track to file an IND and/or CTA by the end of 2025; clinical data
09-30 19:06
